nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—Drug interaction—Carmustine—malignant glioma	0.0127	0.0252	CcSEcCtD
Valsartan—Viral infection—Temozolomide—malignant glioma	0.0126	0.0251	CcSEcCtD
Valsartan—Hepatic enzyme increased—Temozolomide—malignant glioma	0.012	0.0239	CcSEcCtD
Valsartan—Swelling—Carmustine—malignant glioma	0.00966	0.0193	CcSEcCtD
Valsartan—Hyponatraemia—Carmustine—malignant glioma	0.00855	0.0171	CcSEcCtD
Valsartan—Muscular weakness—Carmustine—malignant glioma	0.00751	0.015	CcSEcCtD
Valsartan—Irbesartan—PTGS1—malignant glioma	0.00739	0.5	CrCbGaD
Valsartan—Candesartan—PTGS1—malignant glioma	0.00739	0.5	CrCbGaD
Valsartan—Muscular weakness—Temozolomide—malignant glioma	0.00726	0.0145	CcSEcCtD
Valsartan—Neutropenia—Carmustine—malignant glioma	0.00689	0.0137	CcSEcCtD
Valsartan—Bronchitis—Temozolomide—malignant glioma	0.00684	0.0137	CcSEcCtD
Valsartan—Neutropenia—Temozolomide—malignant glioma	0.00665	0.0133	CcSEcCtD
Valsartan—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00661	0.0132	CcSEcCtD
Valsartan—Erectile dysfunction—Temozolomide—malignant glioma	0.00655	0.0131	CcSEcCtD
Valsartan—Photosensitivity reaction—Temozolomide—malignant glioma	0.0065	0.013	CcSEcCtD
Valsartan—Renal failure—Carmustine—malignant glioma	0.00645	0.0129	CcSEcCtD
Valsartan—Infestation NOS—Temozolomide—malignant glioma	0.00635	0.0127	CcSEcCtD
Valsartan—Infestation—Temozolomide—malignant glioma	0.00635	0.0127	CcSEcCtD
Valsartan—Sinusitis—Temozolomide—malignant glioma	0.00595	0.0119	CcSEcCtD
Valsartan—Haemoglobin—Carmustine—malignant glioma	0.00592	0.0118	CcSEcCtD
Valsartan—Haemorrhage—Carmustine—malignant glioma	0.00589	0.0118	CcSEcCtD
Valsartan—Connective tissue disorder—Carmustine—malignant glioma	0.00579	0.0116	CcSEcCtD
Valsartan—Haemoglobin—Temozolomide—malignant glioma	0.00572	0.0114	CcSEcCtD
Valsartan—Hepatitis—Temozolomide—malignant glioma	0.0057	0.0114	CcSEcCtD
Valsartan—Haemorrhage—Temozolomide—malignant glioma	0.0057	0.0114	CcSEcCtD
Valsartan—Pharyngitis—Temozolomide—malignant glioma	0.00565	0.0113	CcSEcCtD
Valsartan—Urinary tract disorder—Temozolomide—malignant glioma	0.00563	0.0112	CcSEcCtD
Valsartan—Connective tissue disorder—Temozolomide—malignant glioma	0.0056	0.0112	CcSEcCtD
Valsartan—Urethral disorder—Temozolomide—malignant glioma	0.00558	0.0111	CcSEcCtD
Valsartan—Cardiac disorder—Temozolomide—malignant glioma	0.00529	0.0105	CcSEcCtD
Valsartan—Alopecia—Carmustine—malignant glioma	0.00521	0.0104	CcSEcCtD
Valsartan—Angiopathy—Temozolomide—malignant glioma	0.00517	0.0103	CcSEcCtD
Valsartan—Mental disorder—Carmustine—malignant glioma	0.00516	0.0103	CcSEcCtD
Valsartan—Immune system disorder—Temozolomide—malignant glioma	0.00514	0.0103	CcSEcCtD
Valsartan—Mediastinal disorder—Temozolomide—malignant glioma	0.00513	0.0102	CcSEcCtD
Valsartan—Malnutrition—Carmustine—malignant glioma	0.00513	0.0102	CcSEcCtD
Valsartan—Alopecia—Temozolomide—malignant glioma	0.00503	0.01	CcSEcCtD
Valsartan—Mental disorder—Temozolomide—malignant glioma	0.00499	0.00996	CcSEcCtD
Valsartan—Back pain—Carmustine—malignant glioma	0.00496	0.0099	CcSEcCtD
Valsartan—Malnutrition—Temozolomide—malignant glioma	0.00496	0.00989	CcSEcCtD
Valsartan—Dysgeusia—Temozolomide—malignant glioma	0.00486	0.00969	CcSEcCtD
Valsartan—Vision blurred—Carmustine—malignant glioma	0.00484	0.00965	CcSEcCtD
Valsartan—Back pain—Temozolomide—malignant glioma	0.0048	0.00957	CcSEcCtD
Valsartan—Vision blurred—Temozolomide—malignant glioma	0.00467	0.00932	CcSEcCtD
Valsartan—Angioedema—Temozolomide—malignant glioma	0.00453	0.00904	CcSEcCtD
Valsartan—Vertigo—Temozolomide—malignant glioma	0.00445	0.00889	CcSEcCtD
Valsartan—Palpitations—Temozolomide—malignant glioma	0.00438	0.00874	CcSEcCtD
Valsartan—Myalgia—Carmustine—malignant glioma	0.00437	0.00872	CcSEcCtD
Valsartan—Chest pain—Carmustine—malignant glioma	0.00437	0.00872	CcSEcCtD
Valsartan—Anxiety—Carmustine—malignant glioma	0.00435	0.00869	CcSEcCtD
Valsartan—Cough—Temozolomide—malignant glioma	0.00433	0.00863	CcSEcCtD
Valsartan—Myalgia—Temozolomide—malignant glioma	0.00422	0.00842	CcSEcCtD
Valsartan—Arthralgia—Temozolomide—malignant glioma	0.00422	0.00842	CcSEcCtD
Valsartan—Anxiety—Temozolomide—malignant glioma	0.00421	0.00839	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00419	0.00836	CcSEcCtD
Valsartan—Oedema—Carmustine—malignant glioma	0.00419	0.00836	CcSEcCtD
Valsartan—Infection—Carmustine—malignant glioma	0.00416	0.0083	CcSEcCtD
Valsartan—Dry mouth—Temozolomide—malignant glioma	0.00413	0.00824	CcSEcCtD
Valsartan—Thrombocytopenia—Carmustine—malignant glioma	0.0041	0.00818	CcSEcCtD
Valsartan—Anaphylactic shock—Temozolomide—malignant glioma	0.00405	0.00807	CcSEcCtD
Valsartan—Oedema—Temozolomide—malignant glioma	0.00405	0.00807	CcSEcCtD
Valsartan—Infection—Temozolomide—malignant glioma	0.00402	0.00802	CcSEcCtD
Valsartan—Anorexia—Carmustine—malignant glioma	0.00399	0.00796	CcSEcCtD
Valsartan—Nervous system disorder—Temozolomide—malignant glioma	0.00397	0.00792	CcSEcCtD
Valsartan—Thrombocytopenia—Temozolomide—malignant glioma	0.00396	0.00791	CcSEcCtD
Valsartan—Skin disorder—Temozolomide—malignant glioma	0.00393	0.00784	CcSEcCtD
Valsartan—Hypotension—Carmustine—malignant glioma	0.00391	0.00781	CcSEcCtD
Valsartan—Anorexia—Temozolomide—malignant glioma	0.00386	0.0077	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00382	0.00761	CcSEcCtD
Valsartan—Insomnia—Carmustine—malignant glioma	0.00379	0.00756	CcSEcCtD
Valsartan—Paraesthesia—Carmustine—malignant glioma	0.00376	0.0075	CcSEcCtD
Valsartan—Dyspnoea—Carmustine—malignant glioma	0.00373	0.00745	CcSEcCtD
Valsartan—Somnolence—Carmustine—malignant glioma	0.00372	0.00743	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00369	0.00736	CcSEcCtD
Valsartan—Insomnia—Temozolomide—malignant glioma	0.00366	0.0073	CcSEcCtD
Valsartan—Decreased appetite—Carmustine—malignant glioma	0.00364	0.00726	CcSEcCtD
Valsartan—Paraesthesia—Temozolomide—malignant glioma	0.00363	0.00725	CcSEcCtD
Valsartan—Gastrointestinal disorder—Carmustine—malignant glioma	0.00362	0.00721	CcSEcCtD
Valsartan—Dyspnoea—Temozolomide—malignant glioma	0.00361	0.0072	CcSEcCtD
Valsartan—Somnolence—Temozolomide—malignant glioma	0.0036	0.00718	CcSEcCtD
Valsartan—Constipation—Carmustine—malignant glioma	0.00358	0.00715	CcSEcCtD
Valsartan—Dyspepsia—Temozolomide—malignant glioma	0.00356	0.00711	CcSEcCtD
Valsartan—Decreased appetite—Temozolomide—malignant glioma	0.00352	0.00702	CcSEcCtD
Valsartan—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00349	0.00697	CcSEcCtD
Valsartan—Fatigue—Temozolomide—malignant glioma	0.00349	0.00696	CcSEcCtD
Valsartan—Constipation—Temozolomide—malignant glioma	0.00346	0.0069	CcSEcCtD
Valsartan—Gastrointestinal pain—Carmustine—malignant glioma	0.00342	0.00683	CcSEcCtD
Valsartan—Abdominal pain—Carmustine—malignant glioma	0.00331	0.00661	CcSEcCtD
Valsartan—Gastrointestinal pain—Temozolomide—malignant glioma	0.00331	0.0066	CcSEcCtD
Valsartan—Urticaria—Temozolomide—malignant glioma	0.00321	0.00641	CcSEcCtD
Valsartan—Abdominal pain—Temozolomide—malignant glioma	0.0032	0.00638	CcSEcCtD
Valsartan—Hypersensitivity—Carmustine—malignant glioma	0.00309	0.00616	CcSEcCtD
Valsartan—Asthenia—Carmustine—malignant glioma	0.003	0.00599	CcSEcCtD
Valsartan—Hypersensitivity—Temozolomide—malignant glioma	0.00298	0.00595	CcSEcCtD
Valsartan—Asthenia—Temozolomide—malignant glioma	0.0029	0.00579	CcSEcCtD
Valsartan—Diarrhoea—Carmustine—malignant glioma	0.00287	0.00572	CcSEcCtD
Valsartan—Pruritus—Temozolomide—malignant glioma	0.00286	0.00571	CcSEcCtD
Valsartan—Dizziness—Carmustine—malignant glioma	0.00277	0.00553	CcSEcCtD
Valsartan—Diarrhoea—Temozolomide—malignant glioma	0.00277	0.00552	CcSEcCtD
Valsartan—Dizziness—Temozolomide—malignant glioma	0.00268	0.00534	CcSEcCtD
Valsartan—Vomiting—Carmustine—malignant glioma	0.00266	0.00531	CcSEcCtD
Valsartan—Rash—Carmustine—malignant glioma	0.00264	0.00527	CcSEcCtD
Valsartan—Dermatitis—Carmustine—malignant glioma	0.00264	0.00526	CcSEcCtD
Valsartan—Headache—Carmustine—malignant glioma	0.00262	0.00523	CcSEcCtD
Valsartan—Vomiting—Temozolomide—malignant glioma	0.00257	0.00513	CcSEcCtD
Valsartan—Rash—Temozolomide—malignant glioma	0.00255	0.00509	CcSEcCtD
Valsartan—Dermatitis—Temozolomide—malignant glioma	0.00255	0.00509	CcSEcCtD
Valsartan—Headache—Temozolomide—malignant glioma	0.00254	0.00506	CcSEcCtD
Valsartan—Nausea—Carmustine—malignant glioma	0.00249	0.00496	CcSEcCtD
Valsartan—Nausea—Temozolomide—malignant glioma	0.0024	0.0048	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—malignant glioma	0.000445	0.00092	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MMP3—malignant glioma	0.000444	0.000918	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.00044	0.000909	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000429	0.000887	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAG2—malignant glioma	0.000425	0.000878	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—malignant glioma	0.000417	0.000862	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.000414	0.000856	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—IDH2—malignant glioma	0.000412	0.000851	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PDGFB—malignant glioma	0.000407	0.000841	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTT1—malignant glioma	0.000404	0.000835	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	0.000389	0.000803	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2B6—malignant glioma	0.000387	0.0008	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS1—malignant glioma	0.000379	0.000783	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000378	0.00078	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—malignant glioma	0.000376	0.000777	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.000372	0.000769	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—FN1—malignant glioma	0.000367	0.000758	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—F2—malignant glioma	0.000367	0.000758	CbGpPWpGaD
Valsartan—ALB—Metabolism—COX8A—malignant glioma	0.000365	0.000755	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.00036	0.000744	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—H3F3A—malignant glioma	0.00036	0.000743	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—F2—malignant glioma	0.000357	0.000738	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCR3—malignant glioma	0.000356	0.000736	CbGpPWpGaD
Valsartan—ALB—Hemostasis—H3F3A—malignant glioma	0.000355	0.000734	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—IDH1—malignant glioma	0.000354	0.000732	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—BCHE—malignant glioma	0.000352	0.000728	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CG—malignant glioma	0.000351	0.000726	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC5A5—malignant glioma	0.000348	0.000719	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—EGF—malignant glioma	0.000347	0.000717	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—YWHAE—malignant glioma	0.000346	0.000716	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NTRK2—malignant glioma	0.000346	0.000716	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FLT1—malignant glioma	0.000345	0.000712	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—DUSP6—malignant glioma	0.000343	0.000709	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SPHK1—malignant glioma	0.000343	0.000708	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CG—malignant glioma	0.000342	0.000706	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAG1—malignant glioma	0.000339	0.0007	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH3—malignant glioma	0.000338	0.000697	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2C18—malignant glioma	0.000336	0.000694	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FBXW7—malignant glioma	0.000332	0.000686	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	0.000329	0.00068	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000327	0.000675	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	0.000326	0.000674	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BDKRB2—malignant glioma	0.000326	0.000673	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—F2—malignant glioma	0.000324	0.00067	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT2—malignant glioma	0.000321	0.000664	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—RAF1—malignant glioma	0.00032	0.000662	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.000317	0.000654	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT2—malignant glioma	0.000313	0.000646	CbGpPWpGaD
Valsartan—ALB—Metabolism—ASMT—malignant glioma	0.000311	0.000642	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TFRC—malignant glioma	0.000311	0.000642	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CG—malignant glioma	0.00031	0.000641	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CD—malignant glioma	0.000309	0.000638	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTPN11—malignant glioma	0.000305	0.00063	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000304	0.000627	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH2—malignant glioma	0.000303	0.000626	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CD—malignant glioma	0.0003	0.00062	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—COX8A—malignant glioma	0.000299	0.000618	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KNG1—malignant glioma	0.000296	0.000612	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KNG1—malignant glioma	0.000293	0.000605	CbGpPWpGaD
Valsartan—ALB—Metabolism—BCAN—malignant glioma	0.000292	0.000603	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000289	0.000596	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA2—malignant glioma	0.000287	0.000593	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000285	0.000589	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	0.000284	0.000587	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT2—malignant glioma	0.000284	0.000586	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NTRK1—malignant glioma	0.000282	0.000583	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTP1—malignant glioma	0.00028	0.000579	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.000278	0.000575	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RAF1—malignant glioma	0.000276	0.00057	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CD—malignant glioma	0.000273	0.000563	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CAT—malignant glioma	0.000273	0.000563	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SOD1—malignant glioma	0.000272	0.000562	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTT1—malignant glioma	0.000272	0.000561	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000271	0.000561	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CB—malignant glioma	0.000269	0.000556	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000267	0.000552	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP3—malignant glioma	0.000263	0.000542	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000262	0.000541	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN2B—malignant glioma	0.00026	0.000538	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NCOR1—malignant glioma	0.000258	0.000532	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS1—malignant glioma	0.000255	0.000526	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ASMT—malignant glioma	0.000254	0.000525	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000254	0.000524	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTK2—malignant glioma	0.000253	0.000522	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—malignant glioma	0.000252	0.00052	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PTK2—malignant glioma	0.00025	0.000516	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000249	0.000513	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HES1—malignant glioma	0.000248	0.000513	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—malignant glioma	0.000247	0.000511	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NCOR1—malignant glioma	0.000247	0.00051	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RAF1—malignant glioma	0.000243	0.000503	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—malignant glioma	0.00024	0.000497	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BCAN—malignant glioma	0.000239	0.000494	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CB—malignant glioma	0.000238	0.000491	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—BCHE—malignant glioma	0.000237	0.000489	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFRA—malignant glioma	0.000236	0.000488	CbGpPWpGaD
Valsartan—ALB—Metabolism—IDH2—malignant glioma	0.000235	0.000486	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC5A5—malignant glioma	0.000234	0.000483	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SPP1—malignant glioma	0.000229	0.000474	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—malignant glioma	0.000228	0.000472	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	0.000222	0.000459	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2B6—malignant glioma	0.000221	0.000457	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	0.000221	0.000457	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	0.000219	0.000453	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—malignant glioma	0.000218	0.000451	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—malignant glioma	0.000218	0.000449	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RAF1—malignant glioma	0.000215	0.000445	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDGFB—malignant glioma	0.000212	0.000439	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGFR1—malignant glioma	0.000211	0.000436	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—malignant glioma	0.00021	0.000434	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CAV1—malignant glioma	0.00021	0.000434	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PDGFB—malignant glioma	0.00021	0.000433	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—malignant glioma	0.000208	0.00043	CbGpPWpGaD
Valsartan—ALB—Metabolism—IDH1—malignant glioma	0.000202	0.000418	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CAV1—malignant glioma	0.000201	0.000416	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	0.000201	0.000414	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—malignant glioma	0.000199	0.000411	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CAV1—malignant glioma	0.000199	0.000411	CbGpPWpGaD
Valsartan—ALB—Metabolism—SPHK1—malignant glioma	0.000196	0.000405	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—IDH2—malignant glioma	0.000193	0.000398	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2C18—malignant glioma	0.000192	0.000397	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—F2—malignant glioma	0.000192	0.000396	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—malignant glioma	0.000192	0.000396	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—malignant glioma	0.000191	0.000395	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	0.000191	0.000395	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BAD—malignant glioma	0.000189	0.000391	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—malignant glioma	0.000189	0.000391	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F2—malignant glioma	0.000189	0.000391	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—malignant glioma	0.000188	0.000389	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH1—malignant glioma	0.000187	0.000387	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—malignant glioma	0.000185	0.000381	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD80—malignant glioma	0.000184	0.000379	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—malignant glioma	0.000183	0.000379	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APC—malignant glioma	0.000183	0.000379	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAT—malignant glioma	0.000183	0.000379	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	0.000182	0.000375	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2B6—malignant glioma	0.000181	0.000374	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGF—malignant glioma	0.000181	0.000374	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—malignant glioma	0.000181	0.000374	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.000181	0.000374	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTPN11—malignant glioma	0.00018	0.000372	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EGF—malignant glioma	0.000179	0.00037	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PTPN11—malignant glioma	0.000178	0.000368	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NCOR1—malignant glioma	0.000173	0.000358	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—malignant glioma	0.000172	0.000356	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—malignant glioma	0.000168	0.000347	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT2—malignant glioma	0.000168	0.000346	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—malignant glioma	0.000167	0.000345	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—IDH1—malignant glioma	0.000166	0.000342	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT2—malignant glioma	0.000166	0.000342	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000165	0.000341	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	0.000164	0.000339	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—malignant glioma	0.000161	0.000333	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SPHK1—malignant glioma	0.00016	0.000331	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—malignant glioma	0.00016	0.00033	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—malignant glioma	0.000159	0.000329	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.000159	0.000329	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—malignant glioma	0.000158	0.000326	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2C18—malignant glioma	0.000157	0.000325	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—malignant glioma	0.000155	0.000321	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF2—malignant glioma	0.000154	0.000319	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.000148	0.000306	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—malignant glioma	0.000147	0.000303	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS1—malignant glioma	0.000145	0.000301	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—malignant glioma	0.000145	0.0003	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000145	0.000299	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—malignant glioma	0.000145	0.000299	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—malignant glioma	0.000144	0.000298	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAF1—malignant glioma	0.000144	0.000297	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—malignant glioma	0.000142	0.000294	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAF1—malignant glioma	0.000142	0.000294	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAV1—malignant glioma	0.000141	0.000291	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—malignant glioma	0.00014	0.00029	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—malignant glioma	0.000139	0.000287	CbGpPWpGaD
Valsartan—ALB—Metabolism—BCHE—malignant glioma	0.000135	0.000279	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—malignant glioma	0.000135	0.000279	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000135	0.000279	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	0.000135	0.000278	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	0.000134	0.000277	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC5A5—malignant glioma	0.000134	0.000276	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—malignant glioma	0.00013	0.000269	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.00013	0.000269	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—malignant glioma	0.000129	0.000267	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—malignant glioma	0.000129	0.000266	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—malignant glioma	0.000128	0.000265	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—malignant glioma	0.000127	0.000263	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—malignant glioma	0.000127	0.000262	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—malignant glioma	0.000127	0.000262	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	0.000126	0.000261	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	0.000125	0.000259	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—malignant glioma	0.000124	0.000256	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	0.000123	0.000254	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—malignant glioma	0.000122	0.000252	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—malignant glioma	0.000121	0.000251	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS1—malignant glioma	0.000119	0.000246	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000119	0.000245	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—malignant glioma	0.000118	0.000245	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—malignant glioma	0.000113	0.000233	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BCHE—malignant glioma	0.000111	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—malignant glioma	0.00011	0.000226	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC5A5—malignant glioma	0.000109	0.000226	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	0.000109	0.000226	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—malignant glioma	0.000109	0.000224	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—malignant glioma	0.000108	0.000224	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—malignant glioma	0.000108	0.000222	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAT—malignant glioma	0.000105	0.000216	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	0.000103	0.000214	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	0.000102	0.000212	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—malignant glioma	0.000101	0.000208	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOR1—malignant glioma	9.89e-05	0.000204	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—malignant glioma	9.86e-05	0.000204	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—malignant glioma	9.85e-05	0.000203	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—malignant glioma	9.76e-05	0.000202	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—malignant glioma	9.32e-05	0.000193	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—malignant glioma	9.21e-05	0.00019	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	8.93e-05	0.000185	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—malignant glioma	8.93e-05	0.000185	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—malignant glioma	8.81e-05	0.000182	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAT—malignant glioma	8.57e-05	0.000177	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—malignant glioma	8.56e-05	0.000177	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—malignant glioma	8.51e-05	0.000176	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—malignant glioma	8.46e-05	0.000175	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—malignant glioma	8.28e-05	0.000171	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—malignant glioma	8.18e-05	0.000169	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOR1—malignant glioma	8.09e-05	0.000167	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAV1—malignant glioma	8.06e-05	0.000167	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.7e-05	0.000159	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—malignant glioma	7.34e-05	0.000152	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—malignant glioma	7.3e-05	0.000151	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—malignant glioma	7.09e-05	0.000146	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—malignant glioma	6.99e-05	0.000144	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—malignant glioma	6.91e-05	0.000143	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAV1—malignant glioma	6.6e-05	0.000136	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—malignant glioma	6.45e-05	0.000133	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.3e-05	0.00013	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—malignant glioma	6.01e-05	0.000124	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—malignant glioma	6e-05	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—malignant glioma	5.8e-05	0.00012	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—malignant glioma	5.63e-05	0.000116	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—malignant glioma	5.57e-05	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—malignant glioma	5.28e-05	0.000109	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—malignant glioma	4.9e-05	0.000101	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—malignant glioma	4.86e-05	0.0001	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—malignant glioma	4.6e-05	9.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—malignant glioma	4.56e-05	9.43e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—malignant glioma	3.98e-05	8.22e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—malignant glioma	3.43e-05	7.08e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.81e-05	5.8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—malignant glioma	2.8e-05	5.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—malignant glioma	2.29e-05	4.74e-05	CbGpPWpGaD
